ArticleKidney international supplements2012
Chapter 7: Idiopathic membranous nephropathy.
Article in Kidney international supplements, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis.Stem cell research & therapy · 2020Pooled it
- Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis.Drug design, development and therapy · 2019Pooled it
- Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.The Cochrane database of systematic reviews · 2014Pooled it
- Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome.The Cochrane database of systematic reviews · 2013Pooled it
- Efficacy and safety of Mahuang Fuzi and Shenzhuo Decoction for treatment of primary membranous nephropathy: a multicenter prospective trial.Renal failure · 2024Trial
- A preliminary nomogram model for predicting relapse of patients with primary membranous nephropathy.Renal failure · 2023Trial
- Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.Lancet (London, England) · 2013Trial
- Anti-PLA2R antibody levels and clinical risk factors for predicting relapse in primary membranous nephropathy.Frontiers in immunology · 2026Article
- Clinical effect of obinutuzumab in the treatment of idiopathic membranous nephropathy.American journal of translational research · 2026Article
- Clinicopathological characteristics of neural epidermal growth factor-like 1 protein-associated membranous glomerulonephritis.Virchows Archiv : an international journal of pathology · 2025Article
- Synchronous papillary renal neoplasm with reverse polarity and membranous nephropathy: a rare case report.Frontiers in oncology · 2025Article
- Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies.Renal failure · 2024Article
- Effects of immunosuppressive therapy on renal prognosis in primary membranous nephropathy.BMC nephrology · 2024Article
- The efficacy and safety of Sanqi Qushi Granule in patients with idiopathic membranous nephropathy --protocol of a multicenter, randomized control trial (SQ-AUTUMN).BMC complementary medicine and therapies · 2023Article
- The Role of Anti-PLAInternational journal of environmental research and public health · 2022Review
- Review
- The optimal anti-phospholipase A2 receptor cutoff for the diagnosis of idiopathic membranous nephropathy: a single-center retrospective study.The Korean journal of internal medicine · 2022Article
- Hypercholesterolemia Correlates With Glomerular Phospholipase A2 Receptor Deposit and Serum Anti-Phospholipase A2 Receptor Antibody and Predicts Proteinuria Outcome in Idiopathic Membranous Nephropathy.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.